A molecular genetics view on Mucopolysaccharidosis Type II

Area of Science:

• Genetics
• Biochemistry
• Rare Diseases

Background:

• Mucopolysaccharidosis Type II (MPS II) is an X-linked recessive orphan disease affecting males, with an incidence of 1 in 100,000 live births.
• Caused by mutations in the lysosomal iduronate-2-sulfatase (IDS) gene, leading to glycosaminoglycan (GAG) accumulation and multi-organ damage.
• Disease presentation varies from severe neurological to attenuated courses, with the precise link between mutation, GAG levels, and progression still under investigation.

Purpose of the Study:

• To review current diagnostic methods and therapeutic interventions for MPS II.
• To elucidate the impact of genetic diversity within the IDS gene on disease phenotype.
• To explore implications of genetic variations for diagnosis, prognosis, and therapy, considering future drug design.

Main Methods:

• Review of current diagnostic procedures for MPS II.
• Analysis of therapeutic interventions for MPS II.
• Examination of genetic diversity within the IDS gene and its phenotypic correlations.
• Incorporation of recent advances in structural biology of the I2S enzyme.

Main Results:

• Identification of IDS gene mutations as the cause of MPS II.
• Demonstration of GAG accumulation (heparan sulfate and dermatan sulfate) due to enzymatic deficiency.
• Observation of varied disease severity linked to genetic mutations.
• Highlighting the role of genetic profile in assessing therapeutic success.

Conclusions:

• Understanding IDS gene variants is crucial for predicting disease course and guiding treatment.
• Structural biological insights into the I2S enzyme are advancing the understanding of molecular damage.
• Further research into genetic diversity will improve diagnostic accuracy, prognostic capabilities, and therapeutic strategies for MPS II.
• Personalized medicine approaches, informed by genetic profiles, hold promise for future MPS II management.